Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Eckert & Ziegler Strahlen- und Medizintechnik AG buy fabinator

Start price
€19.63
12.04.19 / 50%
Target price
€25.00
15.05.19
Performance (%)
29.94%
End price
€25.50
15.05.19
Summary
This prediction ended on 15.05.19 with a price of €25.50. The prediction had a final performance of 29.94%. fabinator has a follow-up prediction for Eckert & Ziegler Strahlen- und Medizintechnik AG where he still thinks Eckert & Ziegler Strahlen- und Medizintechnik AG is a Buy. fabinator has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Eckert & Ziegler Strahlen- und Medizintechnik AG 1.205% 1.205% -20.890% -54.899%
iShares Core DAX® -0.992% -3.231% 11.661% 16.545%
iShares Nasdaq 100 -0.225% -3.339% 36.491% 43.334%
iShares Nikkei 225® -0.736% -7.859% 18.597% 4.253%
iShares S&P 500 -0.509% -2.979% 26.341% 40.911%

According to fabinator what are the pros and cons of Eckert & Ziegler Strahlen- und Medizintechnik AG for the foreseeable future?

Pros
Higher EBIT margin than peer group
Revenue growth >5% per year expected
EBIT growth >5% per year expected
positive Cash Flow expected
Good rating
Standard Investments for future growth
Very capable Management
Very good company culture
Leading role in innovation
Strong uniques
Very differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Market Leader or Top 3
Small cyclical dependencies
Very Future proof/growth oriented business model
Cons
High valuation
Low dividend yield expected

Comments by fabinator for this prediction

In the thread Eckert & Ziegler AG diskutieren
Prediction Buy
Perf. (%) 29.94%
Target price 100.000
Change
Ends at 15.05.19

Rücksetzer als Chance

Nach dem Rücksetzer auf unter 80€ gibts hier einige Chancen, dass der Kurs wieder steigt.



- Der Finanzmittelbestand zum 31. Dezember 2018 betrug: 54,2 Mio. EUR, keine Schulden
- Prognose für das Geschäftsjahr 2019:
 Umsatz ca. 180 Mio. EUR, EBIT ca. 23,5 Mio., Konzerngewinn ca. 18 Mio. EUR (3,50 EUR pro Aktie)

- Ende Mai 2019 Divdende von 1,20 pro Aktie.






Prediction Buy
Perf. (%) 29.94%
Target price 100.000
Change
Ends at 15.05.19

(Zielkurs erreicht)

Current prediction by fabinator for Eckert & Ziegler Strahlen- und Medizintechnik AG

buy
Eckert & Ziegler Strahlen- und Medizintechnik AG

Start price
Target price
Perf. (%)
€48.92
25.04.22
€120.00
03.02.25
-23.43%
30.04.24

Higher EBIT margin than peer group
Revenue growth >5% per year expected
EBIT growth >5% per year expected
High valuation